The benefits were observed regardless of diabetes status, prompting the inclusion of SGLT-2 inhibitors in the American College of Cardiology and American Heart Association (AHA) treatment guidelines for HFrEF [17]. Here, SLC5A2 is linked to diabetes mellitus.